102 related articles for article (PubMed ID: 7577090)
1. Different doses of epirubicin associated with fixed doses of cyclophosphamide and 5-fluorouracil: a randomised study in advanced breast cancer.
Riccardi A; Giordano M; Brugnatelli S; Ucci G; Danova M; Mora O; Fava S; Ascari E
Eur J Cancer; 1995; 31A(9):1549-51. PubMed ID: 7577090
[No Abstract] [Full Text] [Related]
2. A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer.
Levine MN; Bramwell V; Pritchard K; Perrault D; Findlay B; Abu-Zahra H; Warr D; Arnold A; Skillings J
Eur J Cancer; 1992; 29A(1):37-43. PubMed ID: 1445744
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of advanced cancer of the breast with FEC polychemotherapy using epirubicin at 75 mg/m2 dose (FEC 75)].
Perez Carrion R; Jimeno JM; Jimenez V; Guardiola L; Donnay O; Sanchez J
Bull Cancer; 1990; 77(10):1033-5. PubMed ID: 2249014
[No Abstract] [Full Text] [Related]
4. 5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer.
Lopez M; Papaldo P; Di Lauro L; Vici P; Carpano S; Conti EM
Oncology; 1989; 46(1):1-5. PubMed ID: 2915887
[TBL] [Abstract][Full Text] [Related]
5. Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM).
Colucci G; Romito S; Gebbia V; Pacilio G; Giotta F; Testa A; Pezzella G; Durini E; Agostara B; Cariello S
Br J Cancer; 1995 Nov; 72(5):1245-50. PubMed ID: 7577476
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
[TBL] [Abstract][Full Text] [Related]
8. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.
Bergh J; Wiklund T; Erikstein B; Lidbrink E; Lindman H; Malmström P; Kellokumpu-Lehtinen P; Bengtsson NO; Söderlund G; Anker G; Wist E; Ottosson S; Salminen E; Ljungman P; Holte H; Nilsson J; Blomqvist C; Wilking N
Lancet; 2000 Oct; 356(9239):1384-91. PubMed ID: 11052580
[TBL] [Abstract][Full Text] [Related]
9. Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer.
Boccardo F; Amadori D; Guglielmini P; Sismondi P; Farris A; Agostara B; Gambi A; Catalano G; Faedi M; Rubagotti A
Oncology; 2010; 78(3-4):274-81. PubMed ID: 20530973
[TBL] [Abstract][Full Text] [Related]
10. Concurrent administration of chemo-endocrine therapy for postmenopausal breast cancer patients.
Watanabe N; Ootawa Y; Kodama K; Kaide A; Ootsuka N; Matsuoka J
Breast Cancer; 2010 Oct; 17(4):247-53. PubMed ID: 19728030
[TBL] [Abstract][Full Text] [Related]
11. High-dose epirubicin + cyclophosphamide (HD-EC) in metastatic breast cancer: a dose-finding study.
Nagel GA; Beyer JH; Holtkamp W; Emrich D; Kneba M; Luig H; Marschner N; Rauschning W; Unger C; Wander HE
Onkologie; 1988 Dec; 11(6):287-8. PubMed ID: 3071764
[No Abstract] [Full Text] [Related]
12. [Neoadjuvant treatment for locally advanced breast cancer. Comparison of two schemes based on docetaxel-epirubicin vs. 5-fluorouracil-epirubicin-cyclophosphamide].
Cortés-Flores AO; Morgan-Villela G; Castro-Cervantes JM; Vázquez-Camacho G; Fuentes-Orozco C; González-Ojeda A
Cir Cir; 2008; 76(1):23-8. PubMed ID: 18492416
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer.
Amadori D; Silvestrini R; De Lena M; Boccardo F; Rocca A; Scarpi E; Schittulli F; Brandi M; Maltoni R; Serra P; Ponzone R; Biglia N; Gianni L; Tienghi A; Valerio MR; Bonginelli P; Amaducci L; Faedi M; Baldini E; Paradiso A
Breast Cancer Res Treat; 2011 Feb; 125(3):775-84. PubMed ID: 21132360
[TBL] [Abstract][Full Text] [Related]
14. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study.
Therasse P; Mauriac L; Welnicka-Jaskiewicz M; Bruning P; Cufer T; Bonnefoi H; Tomiak E; Pritchard KI; Hamilton A; Piccart MJ;
J Clin Oncol; 2003 Mar; 21(5):843-50. PubMed ID: 12610183
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer.
Eisen T; Smith IE; Johnston S; Ellis PA; Prendiville J; Seymour MT; Walsh G; Ashley S
J Clin Oncol; 1998 Apr; 16(4):1350-7. PubMed ID: 9552036
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.
Coombes RC; Bliss JM; Wils J; Morvan F; Espié M; Amadori D; Gambrosier P; Richards M; Aapro M; Villar-Grimalt A; McArdle C; Pérez-López FR; Vassilopoulos P; Ferreira EP; Chilvers CE; Coombes G; Woods EM; Marty M
J Clin Oncol; 1996 Jan; 14(1):35-45. PubMed ID: 8558217
[TBL] [Abstract][Full Text] [Related]
17. Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group.
Del Mastro L; Venturini M; Lionetto R; Carnino F; Guarneri D; Gallo L; Contu A; Pronzato P; Vesentini L; Bergaglio M; Comis S; Rosso R
J Clin Oncol; 2001 Apr; 19(8):2213-21. PubMed ID: 11304774
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
Kimura M; Tominaga T; Takatsuka Y; Toi M; Abe R; Koyama H; Takashima S; Nomura Y; Miura S; Kimijima I; Tashiro H; Ohashi Y;
Breast Cancer; 2010 Jul; 17(3):190-8. PubMed ID: 19575284
[TBL] [Abstract][Full Text] [Related]
19. Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
Kerbrat P; Roché H; Bonneterre J; Veyret C; Lortholary A; Monnier A; Fumoleau P; Fargeot P; Namer M; Chollet P; Goudier MJ; Audhuy B; Simon H; Montcuquet P; Eymard JC; Walter S; Clavère P; Guastalla JP;
Br J Cancer; 2007 Jun; 96(11):1633-8. PubMed ID: 17505516
[TBL] [Abstract][Full Text] [Related]
20. Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93) - the German Adjuvant Breast Cancer Group.
Eiermann W; Graf E; Ataseven B; Conrad B; Hilfrich J; Massinger-Biebl H; Vescia S; Loibl S; von Minckwitz G; Schumacher M; Kaufmann M;
Eur J Cancer; 2010 Jan; 46(1):84-94. PubMed ID: 19879750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
